AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Marilyn Alva
Ivax Corp. is a drug company, but it could write a book about the law.
The feisty firm has won a long, nasty legal battle with the big guys to sella generic version of Taxol, a cancer-fighting blockbuster marketed by Bristol-Myers Squibb Co.
Even after Ivax won its fight in September, Bristol-Myers filed more lawsuits seeking to block the sales. But in appeals rulings in April, the courts continued to side with Ivax.
Ivax President Neil Flanzraich, who holds a law degree from Harvard Law School, likens the battle to David vs. Goliath.
"A small company like us taking on a giant like that -- everybody wrote us off," he said.
No one's writing off Ivax now. Of its $259.9 million in first-quarter sales,more than $50 million came from its lower-priced Taxol version, which it namedOnxol. That follows the $35 million it generated during its launch in the previous quarter.